TearLab technology validated in peer-review journal

TearLab’s (NASDAQ:TEAR;TSX:TLB) point-of-care osmolarity test is the technology of choice to aid in the diagnosis of Dry Eye Disease (“DED”) according to a peer-reviewed article published in the current issue of Contact Lens & Anterior Eye, the official journal of the British Contact Lens Association.

The article states that while tear osmolarity has proven to be the most accurate method for diagnosing and following DED patients, the challenge has been to conduct the test quickly and efficiently.  Until recently, the test was typically performed in a clinical laboratory setting and required large samples of tears, which was often a challenge in patients with severe DED.

“However, these difficulties diminished when in 2008 the TearLab Osmolarity System became commercially available in Europe,” the article said.  “The system is designed to be used in an eye care practitioner’s office, has great ease-of-use and requires a very small volume of tears: 50 nanoliters.”  An abstract of the article is available here.

In a statement, Elias Vamvakas, CEO of TearLab, said that as evidence continues to point to tear film osmolarity as the “preferred tool in the evaluation of patients suffering from dry eye disease, we are thrilled to be able to make our proprietary lab-on-a-chip technology available in most European countries as well as the U.S. and Canada.”